Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Curr Res Transl Med ; 65(1): 40-43, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28340695

RESUMO

INTRODUCTION: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived stromal vascular fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived stromal vascular fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial. PATIENTS AND METHOD: Twelve females, mean age 54.5±10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30months after treatment. RESULTS: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion. CONCLUSION: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived stromal vascular fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.


Assuntos
Tecido Adiposo/citologia , Dedos , Doença de Raynaud/terapia , Escleroderma Sistêmico/terapia , Células Estromais/transplante , Adulto , Idoso , Fracionamento Celular , Células Endoteliais/citologia , Células Endoteliais/transplante , Feminino , Dedos/patologia , Seguimentos , Mãos , Humanos , Injeções Subcutâneas , Pessoa de Meia-Idade , Medidas de Resultados Relatados pelo Paciente , Doença de Raynaud/etiologia , Escleroderma Sistêmico/complicações , Úlcera Cutânea/etiologia , Úlcera Cutânea/terapia , Transplante Autólogo , Resultado do Tratamento
2.
Clin Neurophysiol ; 128(2): 357-364, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28068522

RESUMO

OBJECTIVE: The detection of upper motor neuron (UMN) dysfunction is necessary for the diagnosis of amyotrophic lateral sclerosis (ALS). However, signs of UMN dysfunction may be difficult to establish. This study aimed to determine whether motor-evoked potential (MEP) gain (MEP area/background electromyographic activity) represents an efficient alternative to assess UMN dysfunction. METHODS: MEP area, MEP/compound muscle action potential (CMAP) area ratio, and MEP gain were tested at different force levels in healthy control subjects and ALS patients. Receiver operating characteristic (ROC) curve analyses was used to determine the diagnostic utility of MEP gain and compare it to alternative techniques, namely, diffusion tensor imaging (DTI) and the triple stimulation technique (TST). RESULTS: MEP gain revealed a significant difference between the patients and healthy control subjects in contrast to MEP area and MEP/CMAP area ratio. The diagnostic utility of MEP gain was comparable with that of TST and superior to that of DTI. CONCLUSION: MEP gain can distinguish ALS patients from control subjects and may be helpful for the diagnosis of ALS. SIGNIFICANCE: MEP gain appears to be a useful adjunct test and noninvasive method for the assessment of corticospinal dysfunction.


Assuntos
Esclerose Lateral Amiotrófica/diagnóstico , Eletromiografia/métodos , Potencial Evocado Motor , Tratos Piramidais/fisiopatologia , Esclerose Lateral Amiotrófica/diagnóstico por imagem , Esclerose Lateral Amiotrófica/fisiopatologia , Imagem de Tensor de Difusão/métodos , Eletromiografia/instrumentação , Feminino , Humanos , Masculino
3.
Eur J Pain ; 20(7): 1185-93, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-26914411

RESUMO

BACKGROUND: Algoplus detects acute pain in non-verbal old patients (NVOP) with good psychometric properties. However, depression or dementia might modify the Algoplus score and/or item expression. Algoplus performances on demented and/or depressed old populations were tested. METHODS: This multicentre cross-sectional study included patients ≥65 years old with or without pain assigned to depression, dementia, depression & dementia or control groups. Each group was subjected to the Numerical Rating Scale (NRS) and behavioural scales (Algoplus, Doloplus). Depression and/or dementia status was rated and confirmed by blinded experts. Algoplus psychometric properties tested were: discriminant validity, convergent validity, item analysis, sensitivity to change after pain treatment and threshold determination. RESULTS: The analysis included 171 patients (mean age 82.3 ± 6.3 years). Patients with and without pain in each group were comparable for age in all subgroups, except the older dementia subgroup. The mean Algoplus score was significantly higher for patients with than without pain, regardless of group assignment (Wilcoxon signed-rank test, p < 0.001). Algoplus and NRS or Doloplus had high convergent validity (respective Spearman correlation coefficients 0.79 and 0.87). The mean Algoplus score decreased significantly after starting pain management, regardless of group assignment. Some behaviours (i.e. "look") occurred more often in depressed patients, even those without pain. A threshold of 2 yielded respective sensitivity and specificity values of 95% and 96% for dementia patients, 62% and 79% for depressed patients, 96% and 71% for dementia & depressed patients, and 80% and 100% for controls. CONCLUSION: Algoplus accurately detected pain in depressed and/or dementia patients; and was sensitive to change after pain treatment. WHAT DOES THIS STUDY ADD?: Algoplus accurately detects pain in depressed and/or demented patients. A cut-off score of 2 accurately detects the need for pain management in these populations. Algoplus is sensitive to change after treating pain.


Assuntos
Dor Aguda/diagnóstico , Dor Aguda/psicologia , Demência/complicações , Transtorno Depressivo/complicações , Medição da Dor , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Masculino , Psicometria , Sensibilidade e Especificidade
4.
Acta Psychiatr Scand ; 132(4): 244-56, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26038817

RESUMO

OBJECTIVE: Psychosocial trauma during childhood is associated with schizophrenia vulnerability. The pattern of grey matter decrease is similar to brain alterations seen in schizophrenia. Our objective was to explore the links between childhood trauma, brain morphology and schizophrenia symptoms. METHOD: Twenty-one patients with schizophrenia stabilized with atypical antipsychotic monotherapy and 30 healthy control subjects completed the study. Anatomical MRI images were analysed using optimized voxel-based morphometry (VBM). Childhood trauma was assessed with the Childhood Trauma Questionnaire, and symptoms were rated on the Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) (disorganization, positive and negative symptoms). In the schizophrenia group, we used structural equation modelling in a path analysis. RESULTS: Total grey matter volume was negatively associated with emotional neglect (EN) in patients with schizophrenia. Whole-brain VBM analyses of grey matter in the schizophrenia group revealed a specific inversed association between EN and the right dorsolateral prefrontal cortex (DLPFC). Path analyses identified a well-fitted model in which EN predicted grey matter density in DLPFC, which in turn predicted the disorganization score. CONCLUSION: Our findings suggest that EN during childhood could have an impact on psychopathology in schizophrenia, which would be mediated by developmental effects on brain regions such as the DLPFC.


Assuntos
Maus-Tratos Infantis/psicologia , Substância Cinzenta/patologia , Córtex Pré-Frontal/patologia , Esquizofrenia Infantil/patologia , Esquizofrenia Hebefrênica/patologia , Adulto , Mapeamento Encefálico , Estudos de Casos e Controles , Criança , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Imageamento por Ressonância Magnética/métodos , Masculino , Valor Preditivo dos Testes , Psicologia , Psicologia do Esquizofrênico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...